Development of a TLR7/8 Agonist Adjuvant Formulation to Overcome Early Life Hyporesponsiveness to DTaP Vaccination

Investigators optimized the formulation delivery system, structure, and immunologic activity of novel small molecule imidazoquinoline TLR7/8 adjuvants towards human infant leukocytes, including dendritic cells.